MIM
ALDX icon

MetLife Investment Management’s Aldeyra Therapeutics ALDX Stock Holding History

MetLife Investment Management’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-29,531
Closed -$153K – 2769
2025
Q4 		$153K Buy
29,531
+11,134
+61% +$57.2K ﹤0.01% 2406
2025
Q3 		$96K Sell
18,397
-9,935
-35% -$51.8K ﹤0.01% 2668
2025
Q2 		$109K Buy
28,332
+233
+0.8% +$602 ﹤0.01% 2505
2025
Q1 		$162K Sell
28,099
-590
-2% -$3.49K ﹤0.01% 2307
2024
Q4 		$143K Hold
28,689
– – ﹤0.01% 2466
2024
Q3 		$155K Hold
28,689
– – ﹤0.01% 2423
2024
Q2 		$95K Buy
28,689
+3,883
+16% +$15.2K ﹤0.01% 2634
2024
Q1 		$81.1K Buy
24,806
+125
+0.5% +$411 ﹤0.01% 2625
2023
Q4 		$86.6K Hold
24,681
– – ﹤0.01% 2663
2023
Q3 		$165K Hold
24,681
– – ﹤0.01% 2314
2023
Q2 		$207K Buy
+24,681
New +$243K ﹤0.01% 2257
2022
Q2 		– Sell
-14,311
Closed -$63.6K – 2856
2022
Q1 		$63.6K Sell
14,311
-4,404
-24% -$17.5K ﹤0.01% 2661
2021
Q4 		$74.9K Buy
18,715
+9,298
+99% +$70.9K ﹤0.01% 2456
2021
Q3 		$82.7K Sell
9,417
-9,627
-51% -$88.4K ﹤0.01% 2499
2021
Q2 		$216K Buy
+19,044
New +$229K ﹤0.01% 2120

Other funds holding ALDX

KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

MetLife Investment Management's ALDX Position: Q1 2026 in Review

MetLife Investment Management sold out of Aldeyra Therapeutics (ALDX) in Q1 2026, closing a stake of 29,531 shares — an estimated $153K sold.

MetLife Investment Management first reported a position in ALDX in Q2 2021 and held it in 15 quarters. The position peaked at $216K in Q2 2021. 126 funds tracked by Wall St. Rank hold ALDX as of Q1 2026.

  • MetLife Investment Management reported no remaining Aldeyra Therapeutics position as of Q1 2026 after selling out during the quarter.
  • MetLife Investment Management sold 29,531 Aldeyra Therapeutics shares in Q1 2026, an estimated $153K.
  • MetLife Investment Management first reported a position in Aldeyra Therapeutics in Q2 2021 and held it in 15 quarters.
  • MetLife Investment Management's Aldeyra Therapeutics position peaked at $216K in Q2 2021.
  • 126 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.